
News|Articles|February 1, 2012
FDA Pipeline Preview, February 2012 (Bristol-Myers Squibb, AstraZeneca, Columbia Laboratories, Watson Pharmaceuticals, Achillion, Catalyst Pharmaceutical Partners, AlloCure, Neurocrine Biosciences, AiCuris, CanBas, Pinnacle Biologics, Ikaria)
Recent FDA action (through January 2012) related to dapagliflozin, progesterone vaginal gel 8%, ACH-1625 protease inhibitor, CPP-115 GABA aminotransferase inhibitor, AC607, NBI-98854 VMAT2 inhibitor, AIC246 inhibitor, CBP501, Porfimer sodium, inhaled nitric oxide, carbamazepine extended-release capsules, levetiracetam extended-release tablets
Advertisement
Complete response
Not recommended forapproval
Orphan drug designations
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
HaVy Ngo-Hamilton, Pharm.D. | 2026 MHE Emerging Leaders in Healthcare
2
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2026
3
Healthcare’s workforce has a scale problem, but new model is emerging
4
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
5

























